ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,00%
Bitcoin
63.045,96
0,25%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. DiaMedica Therapeutics Inc (DMAC)

  7. DiaMedica Therapeutics Inc (DMAC) News

DMAC

DiaMedica Therapeutics (DMAC)

DiaMedica Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DMAC
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202414h55Business WireDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024NASDAQ:DMACDiaMedica Therapeutics Inc
17/04/202422h08Business WireDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeNASDAQ:DMACDiaMedica Therapeutics Inc
19/03/202421h15Business WireDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
29/01/202422h13Business WireDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422h12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
22/01/202414h23Business WireDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
16/11/202322h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h28Business WireDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
09/11/202314h25Business WireDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
06/11/202314h23Business WireDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
12/09/202314h13Business WireDiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
06/09/202314h35Business WireDiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
05/09/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
14/08/202322h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
14/08/202322h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
14/08/202322h13Business WireDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
08/08/202314h32Business WireDiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
18/07/202314h30Business WireDiaMedica Therapeutics to Attend the American Academy of Neurology Summer ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
10/07/202322h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:DMACDiaMedica Therapeutics Inc
10/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DMACDiaMedica Therapeutics Inc
30/06/202322h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202322h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202322h11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:DMACDiaMedica Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DMAC

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
USOTC
RHHBY
Roche (QX)
TG
NOV
Novo Nordisk
TG
DBK
Deutsche Bank
TG
D7G
Nel ASA
COIN
ETHUSD
Ethereum
FX
EURJPY
Euro vs Yen
DBI
TDXP
Tec DAX
CCOM
SILVER
SILVER
DBI
DAX
DAX
NYSE
JPM
JP Morgan Chase
TG
DTE
Deutsche Telekom
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten